Member Info for hahahehehoho

This looks like a NHS contract for 1m a month. If successful 5m a month looks a certainty. 37% of rms is a good chunk, we get the best end of the deal .

I actually think the CEO has done a good job . 6 p to 105p is amazing. People expect to much. For these types of companies the foundations are built on the drive, talent and skill of the scientists and employees. Maybe this company does not have that but they have still achieved quite a bit for what they have including £8.2 cash for 2 years according to article.

https://www.fool.co.uk/investing/2020/10/22/interested-in-the-genedrive-share-price-read-this-first/

Allahuakbar, I agree. People also seem also think WHO / FDA qualification is straightforward and if I understand GDR have failed with a WHO TB test before (??).

It shouldn't matter as shareholders should be happy what's happened to the SP here from 6p. People just expect to much these days. If there are too many qualifation problems, GDR should just abandon PCR and focus on covid intact virus testing instead such as LFT or any other type of next gen testing method. Gdr should leave the big boy testing to the people who know what they are doing, Novacyt , Abington Health, Omega, etc...

Directors buying ncyt at 330p was a sign too.

If Boris and the goverment do accept acct into moonshot today or next week, CEO must be unbelievable stupid to of sold today.

Because ncyt are professionals and can be trusted to implement on what they say they will do. They don't make excuses either. Very good management

Interesting and valid view magsy. I'm interested to know what stock is a best buy for you right now?

Of course he is going to say its for a property what else is he going to say?

Mercedes-AMG S65 Coupe

£250k can't buy you any kind of large decent residence in Cambridge area. Lame excuse imo. CEO probably just fed up with manipulation of sp

They should be looking towards next generation testing, like AVCT and BRH. Tests which do not give false positives will be the next big thing next year.
PCR and 20min POC here may be a lost cause for them , as hundreds of companies are competing for global governmental contracts. It is not too late for this company to look to adapt and realize mistakes.

Looks like a solid company here poised to benefit from EV boom

NCYT Tech is 40 years old, but 40000000 times richer than this pretender fighting for ncyt's leftovers.

Drop a bit harsh here on gdr though.

Interesting , and expect partnership details to follow. It should be international pharma or diagnostic company ideally.

Dr Michaels, I don't think ncyt is a cheap hooker! A month after CE approval they already has £17.8m in sales.... That is impressive and no cheap hooker!

4d merger is basically an excuse to get cash and delay a placing.

Gdrs test is absolute b.s. from the wording in the statement it seems it just about meets Mesa requirements. It neither detects intact virus either . 20mins isn't good enough heading into 2021 for next generation testing.

- Carl clearly knows the mhra required settings , so, I expect sensitivity and specificity near enough 97-99% range.
Speed of test for first stage is probably around 5mins. Speed of second test is probably under 30secs.

- I agree , with your statement saying avacta are a bit behind.

- Genedrive have announced a 15min test after having £9m funding and seven months research. The value of the company is £65m and have no sales in PCR.

- Paraytecs 2 stage " transformer," test is fairly unique in that it is lft test and poc test at the same time.

- I expect manufacturing and marketing partners to be announced within 2-3 months for Paraytec . If not, it is in TBs probable interest to sell this company to a larger diagnostic company, (£50-60m?)

The market still needs to close that £250k buy at 50p from Monday and balance the SP. The accumulated sells from Monday still does not cover it , I think we should return to equilibrium early next week or if not earlier

Kainos, Better ask Pro Smythe himself

1509, on twitter ,when Pro Smythe was asked which was the better test between Paraytecs and Avactas, Carl subsequently said there would need to be clinical trials to determine which one. Sounds very much like the tests are similar but with ours having a few extra advantages .

Aptamers and affimers work in quite similar ways. In this case both will bind only to an intact virus protein spike . With paraytec , the difference here is that nanoflourescent particles bind to an intact virus and will show up on their specific machine . Under the light detection they are able to see these particles and detect concentration levels , i.e. state of infection.
In fact, Avacta and Paraytec are quite similar. They both own all IP , both work with universities and both are working on next gen testing. The UK government is only handing out £100m contracts contracts per company initially and Avacta are a few months ahead , but the market cap £10m v £450m is substantial.